Keynote Presentation: Day 2 - Richard Pötter
LDR, HDR, or PDR - Crossroads - Janusz Skowronek
Why Choose Brachytherapy and Not EBRT? - Mitchell Kamrava
Is LDR Brachytherapy Still an Option for Developing Countries? - André-Guy Martin
The Role of HDR Monotherapy for Intermediate-/ High-Risk Prostate Cancer Patients - John K. Hayes, Jr.
The Role of HDR Boost for High-Risk Prostate Cancer Patients - Ferrán Guedea
Prostate Cancer Results Study Group 2014 - Results Comparing Treatment of Prostate Cancer - Peter Grimm
Panel Discussion
| |
If you are viewing this program on a mobile device, please click here.
|